Stock IdeasNov. 13, 2025 2:54 PM ETDay One Biopharmaceuticals, Inc. (DAWN) StockMRSN, DAWNTerry ChrisomalisInvesting Group LeaderCommentsSummaryDay One Biopharmaceuticals, Inc. received FDA approval for OJEMDA, driving strong revenue growth and expansion opportunities in pediatric low-grade glioma.DAWN announces acquisition of Mersana Therapeutics, gaining access to Emi-Le, a promising B7-H4-targeted ADC for solid tumors with unmet medical needs.The merger offers strategic value by diversifying DAWN's pipeline, leveraging positive early data for Emi-Le in ACC-1, and potential in other solid tumors with B7-H4 expression.Maintain a Strong Buy rating on DAWN, citing robust product growth, pipeline expansion, and strategic acquisition, while noting risks around execution and future funding.frentusha/iStock via Getty ImagesThe last time I spoke about Day One Biopharmaceuticals, Inc. (DAWN), it was in a Seeking Alpha article entitled "Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch." With respect to this article, IMore on my IG serviceThis article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.This article was written byTerry Chrisomalis14K FollowersTerry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Comments